Clinical trials: Stage II Prostate Adenocarcinoma
Prostate Cancer
Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00459810
- Testing
- transdermal estradiol, paclitaxel poliglumex
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer
RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging or DCE-MRI and diffusion-weighted imaging or DWI, may provide images of prostate cancer or any cancer that remains after biopsy.
- Trial name
- A6701QIBA (NCT01562223)
- Testing
- motexafin gadolinium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- American College of Radiology Imaging Network
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer
This phase I/II trial studies the side effects and best dose of stereotactic body radiation therapy while using intensity-modulated radiation therapy (IMRT) planning to help avoid radiation to normal tissue in patients with…
- Trial name
- NCT02470897
- Testing
- Radiation Therapy Treatment Planning and Simulation, SBRT
- Where
- 3 sites in United States
- Volunteers
- 115 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation therapy may be an effective treatment for prostate cancer.
- Trial name
- NCT00002480
- Testing
- radiation therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Adenocarcinoma
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate cancer. Relugolix is a form of androgen deprivation therapy.
- Trial name
- NCT06499870
- Testing
- Biopsy, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sean Sachdev
Prostate Cancer, Prostate Adenocarcinoma
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
The purpose of this study is to determine what the safest dose of talazoparib plus temozolomide for participants with metastatic castration resistant prostate cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic
- Trial name
- NCT04019327
- Testing
- Talazoparib, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making androgens.
- Trial name
- NCT00006359
- Testing
- LHRH agonist, antiandrogen, radiation therapy
- Where
- 26 sites in United States
- Volunteers
- 63 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cancer
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
- Trial name
- NCT00161187
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
RATIONALE: Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00046826
- Testing
- docetaxel, estramustine phosphate sodium, thalidomide
- Where
- 2 sites in United States
- Sponsor
- Nuvance Health
Prostate Cancer
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer.
- Trial name
- NCT00027599
- Testing
- bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy
RATIONALE: Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. PURPOSE: This phase II trial is studying the side effects and how well ultrasound-guided implant radiation…
- Trial name
- NCT00450411
- Testing
- 125-Iodine, 103-palladium
- Where
- 17 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Radiation Therapy Oncology Group
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of pasireotide and to see how well it works when given together with docetaxel and prednisone in treating patients with metastatic hormone-resistant prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01468532
- Testing
- docetaxel, pasireotide, prednisone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma
Tivantinib in Treating Patients With Metastatic Prostate Cancer
This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer.
- Conditions
- Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Trial name
- NCT01519414
- Testing
- Laboratory Biomarker Analysis, Tivantinib
- Where
- 20 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Sulforaphane in Treating Patients With Recurrent Prostate Cancer
This phase II trial studies how well sulforaphane works in treating patients with recurrent prostate cancer. Sulforaphane may prevent or slow the growth of certain cancers.
- Trial name
- NCT01228084
- Testing
- Sulforaphane, Laboratory biomarker analysis, Pharmacological study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Calcitriol may help carboplatin kill more cancer cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00017576
- Testing
- calcitriol, carboplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.
- Trial name
- NCT00110162
- Testing
- antiandrogen therapy, releasing hormone agonist therapy, orchiectomy
- Where
- 20 sites in Australia, New Zealand
- Volunteers
- 2,000 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer
Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00589420
- Testing
- docetaxel, sorafenib tosylate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer
RATIONALE: Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Thalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor.
- Trial name
- NCT00400517
- Testing
- sargramostim, thalidomide, conventional surgery
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Cleveland Clinic
Prostate Cancer
Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using exemestane plus bicalutamide may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00031889
- Testing
- Exemestane, Exemestane+bicalutamide
- Where
- 12 sites in Switzerland
- Volunteers
- 5 people
- Sponsor
- Swiss Cancer Institute
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
This partially randomized phase II trial is studying how well giving bicalutamide together with RO4929097 works in treating patients with previously treated prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01200810
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, bicalutamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)